Enter assignee name

EPO Patents = 7

Trademarks = 1

Forward Citations = 4

Loading Chart...

4 inventors (with patents filed for the assignee):

Andreas Bergmann (9 out of 109 patents)

Joachim Struck (1 out of 65 patents)

Nils G Morgenthaler (1 out of 21 patents)

4. Adriaan Voors (1 out of 1 patent)

10 patents: Sort by Forward Citations

1. 12715911 - ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM NON-IG SCAFFOLD FOR USE IN INTERVENTION AND THERAPY OF CONGESTION IN A PATIENT IN NEED THEREOF (2026-08-25),

2. 12338281 - Anti-adrenomedullin antibodies and pharmaceutical compositions thereof (2025-06-24),

3. 11673949 - Method of modulating the adrenomedullin (ADM) activity of a patient by administering to the patient an anti-ADM antibody or fragment thereof that specifically binds to mature human ADM (2023-06-13),

4. 10800842 - Anti-adrenomedullin (ADM) monoclonal antibodies and anti-ADM monoclonal antibody fragments that bind to adrenomedullin (2020-10-13),

5. 10227405 - Methods of modulating the activity of adrenomedullin in a subject in need of regulation of fluid balance by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment (2019-03-12),

6. 10221238 - Method of modulating the activity of adrenomedullin in a subject in need of therapeutic intervention for organ dysfunction or organ failure associated with adranomedullin (ADM) activity by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment to the subject (2019-03-05),

7. 9829494 - Methods of treatment using ADM antibodies (2017-11-28),

8. 9402900 - Methods of modulating adrenomedullin by administering an anti-adrenomedullin (ADM) antibody (2016-08-02),

9. 9304127 - Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy (2016-04-05),

10. 9140696 - Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition (2015-09-22),

Adrenomed AG is a biopharmaceutical company based in Hennigsdorf, Germany, specializing in the development of innovative therapies for critical care and cardiovascular diseases. The company focuses on harnessing the potential of its proprietary technology platform to discover and develop novel treatments aimed at addressing unmet medical needs in acute and chronic conditions. With a commitment to advancing healthcare, Adrenomed AG is dedicated to improving patient outcomes through its research in biomarker-driven therapies and targeted interventions.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

10 Patents

#5 in Hennigsdorf

#3,750 in Germany

#55,986 in the World

Hennigsdorf, Germany

Adrenomed Ag

Forward Citations = 4

4 inventors:

Andreas Bergmann (9 out of 109 patents)

Joachim Struck (1 out of 65 patents)

Nils G Morgenthaler (1 out of 21 patents)

4. Adriaan Voors (1 out of 1 patent)

Please report any incorrect information to [email protected]